摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-methyl-5-o-tolyl-thiazole-4-carboxylic acid methyl ester | 1017272-93-3

中文名称
——
中文别名
——
英文名称
2-methyl-5-o-tolyl-thiazole-4-carboxylic acid methyl ester
英文别名
methyl 2-methyl-5-(2-methylphenyl)-1,3-thiazole-4-carboxylate
2-methyl-5-o-tolyl-thiazole-4-carboxylic acid methyl ester化学式
CAS
1017272-93-3
化学式
C13H13NO2S
mdl
——
分子量
247.318
InChiKey
SZZGLZXNVQNPLH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    375.0±30.0 °C(Predicted)
  • 密度:
    1.189±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    67.4
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS
    申请人:Aissaoui Hamed
    公开号:US20100069418A1
    公开(公告)日:2010-03-18
    The invention relates to piperidine compounds of formula (I) wherein X-R 1 represents —N(H)-pyrimidinyl, wherein said pyrimidinyl is unsubstituted or mono-substituted wherein the substituent is selected from (C 1-4 )alkyl or halogen, or X-R 1 represents —NH—C(O)-heterocyclyl, wherein the heterocyclyl is selected from benzofuranyl and imidazo[2,1-b]-thiazolyl, wherein said heterocyclyl is unsubstituted or independently mono-, di-, or tri-substituted wherein the substituents are independently selected from (C 1-4 )alkyl; A represents a phenyl- or thiazolyl-group, wherein the phenyl or thiazolyl is unsubstituted or mono-substituted with (C 1-4 )alkyl; B represents a phenyl-group, wherein the phenyl is unsubstituted or mono-, or di-substituted, wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, trifluoromethyl, cyano and halogen; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.
    该发明涉及式(I)的哌啶化合物,其中X-R1代表-N(H)-嘧啶基,其中所述的嘧啶基未取代或单取代,取代基选自(C1-4)烷基或卤素,或者X-R1代表-NH-C(O)-杂环基,其中所述的杂环基选自苯并呋喃基和咪唑[2,1-b]-噻唑基,其中所述的杂环基未取代或独立单取代、双取代或三取代,取代基独立选自(C1-4)烷基;A代表苯基或噻唑基,其中所述的苯基或噻唑基未取代或单取代为(C1-4)烷基;B代表苯基,其中所述的苯基未取代或单取代、双取代,取代基独立选自(C1-4)烷基、(C1-4)烷氧基、三甲基、基和卤素;以及其药学上可接受的盐,以及将这类化合物用作药物,特别是用作促觉醒素受体拮抗剂。
  • 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES
    申请人:Aissaoui Hamed
    公开号:US20100016401A1
    公开(公告)日:2010-01-21
    The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R 1 are as described in the description, and salts thereof, and their use as orexin receptor antagonists.
    这项发明涉及式(I)的3-aza-双环[3.1.0]己烷生物,其中A、B、n、X和R1如描述中所述,以及其盐,以及它们作为促进睡眠的荷尔蒙受体拮抗剂的用途。
  • TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES
    申请人:Aissaoui Hamed
    公开号:US20100204285A1
    公开(公告)日:2010-08-12
    The invention relates to novel trans-3-aza-bicyclo[3.1.0]hexane derivatives of formula (I), wherein A, B, n and R 1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.
    该发明涉及新的式子(I)中的trans-3-aza-bicyclo[3.1.0]hexane衍生物,其中A、B、n和R1如说明书所述,并且涉及使用这样的化合物或这样的化合物的药学上可接受的盐作为药物,特别是作为促进睡眠的药物。
  • 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
    申请人:Actelion Pharmaceuticals Ltd.
    公开号:US08133901B2
    公开(公告)日:2012-03-13
    The invention relates to piperidine compounds of formula (I): wherein X—R1 represents —N(H)-pyrimidinyl, wherein said pyrimidinyl is unsubstituted or mono-substituted wherein the substituent is selected from (C1-4)alkyl or halogen, or X—R1 represents —NH—C(O)-heterocyclyl, wherein the heterocyclyl is selected from benzofuranyl and imidazo[2,1-b]-thiazolyl, wherein said heterocyclyl is unsubstituted or independently mono-, di- or tri-substituted wherein the substituents are independently selected from (C1-4)alkyl; A represents a phenyl- or thiazolyl-group, wherein the phenyl or thiazolyl is unsubstituted or mono-substituted with (C1-4)alkyl; B represents a phenyl-group, wherein the phenyl is unsubstituted or mono-, or di- substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, trifluoromethyl, cyano and halogen; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.
    本发明涉及式(I)的哌啶化合物:其中X - R1表示 -N(H)-嘧啶基,其中所述的嘧啶基未取代或单取代,所述取代基从(C1-4)烷基或卤素中选择;或X-R1表示-NH-C(O)-杂环基,所述杂环基从苯并呋喃基和咪唑[2,1-b]-噻唑基中选择,所述杂环基未取代或独立单取代,二取代或三取代,所述取代基独立选择自(C1-4)烷基;A表示苯基或噻唑基,其中苯基或噻唑基未取代或单取代,所述取代基独立选择自(C1-4)烷基;B表示苯基,其中苯基未取代或单取代或二取代,所述取代基独立选择自(C1-4)烷基,(C1-4)烷氧基,三甲基,基和卤素中的一种或多种;以及其制成的药学上可接受的盐,并将此类化合物用作药物,特别是用作促进睡眠的药物。
  • 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS
    申请人:Actelion Pharmaceuticals Ltd.
    公开号:EP2094685A2
    公开(公告)日:2009-09-02
查看更多